Eton Pharmaceuticals, Inc. — Director's Dealing 2021

Aug 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eton Pharmaceuticals, Inc. (ETON)
CIK: 0001710340
Period of Report: 2021-08-20

Reporting Person: BRYNJELSEN SEAN (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-20	Common Stock	P	10000	$4.3200	Acquired	1030000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	24940	Indirect